Tyra Biosciences (TYRA) to Release Earnings on Thursday

Tyra Biosciences (NASDAQ:TYRA) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05. On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tyra Biosciences Stock Down 3.3 %

Shares of TYRA stock opened at $10.50 on Tuesday. The business has a 50 day moving average of $9.77 and a two-hundred day moving average of $13.62. The company has a market cap of $557.45 million, a P/E ratio of -6.52 and a beta of 1.17. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $29.60.

Insider Buying and Selling

In other news, Director Nina S. Kjellson sold 5,401 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the transaction, the director now owns 443,885 shares of the company’s stock, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on TYRA shares. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. UBS Group assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences has a consensus rating of “Buy” and an average target price of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.